FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, B.C. 20043

	OMB APPROVAL									
	OMB Number:	3235-0287								
	Estimated average burden									
l	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>GOLDSTEIN DOV A MD</u>						2. Issuer Name and Ticker or Trading Symbol Esperion Therapeutics, Inc. [ESPR]										elationship eck all appli X Directo	cable)	Reporting Person(s) to Issuer ble) 10% Owner		
(Last) C/O ESP	`	irst) IERAPEUTICS	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 12/18/2017											(give title		Other (s below)	
(Street) ANN AF (City)			48108 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year) Solution 4. If Amendment, Date of Original Filed (Month/Day/Year) Solution 6. Individual or Joint/Group Filing (Che Line) X Form filed by One Reporting Form filed by More than One Person									orting Perso	ı					
		Tab	le I - Nor	n-Deriv	vativ	e Se	curit	ties Ac	qui	ired, D	isp	osed o	f, or	Ben	eficiall	y Owned	l			
Date					ansaction e nth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year		·,	3. Transact Code (Ins 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			(A) or . 3, 4 and		es ally Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership
									Ī	Code	,	Amount	(A) or D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common	Stock			12/1	18/201	17				M ⁽¹⁾		21,47	1	A	\$3.7	21	,518		D	
Common	Stock			12/1	18/201	L7			T	J ⁽¹⁾		21,47	1	D	\$0.00) .	47		D	
		-	Table II -									sed of, onvertil				Owned				•
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution I if any (Month/Day	Date,	4. Transaction Code (Instr. 8)		of Deri Sec Acq (A) (Disp of (I	ivative urities juired or oosed D) (Instr. and 5)	Exp	Date Exer piration D onth/Day/	ate	of Securities		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	i lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Dat	te ercisable		kpiration ate	Title	1	Amount or Number of Shares					
Stock Option (right to buy)	\$3.7	12/18/2017			M ⁽¹⁾			21,471	04	1/11/2013	04	1/11/2023	Comm		21,471	\$0.00	0		D	

Explanation of Responses:

1. The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein.

/s/ Richard B. Bartram, by power of attorney

12/20/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.